RevMed748 2026 RevMed748 2026
Daraxonrasib (Rasonque) was approved by the US FDA for patients with pancreatic adenocarcinoma who had received at least one prior systemic therapy or were not eligible for multi‑agent systemic therapy.
The US FDA has approved Revolution Medicines7 daraxonrasib (Rasonque) for patients with pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not eligible for multiagent systemic therapy. Daraxonrasib is the first broadly active RAS-targeted inhibitor to market, and offers hope for patients with a notoriously hard-to-treat cancer.
The approval of daraxonrasib marks the first broadly active RAS‑targeted inhibitor available on the market, expanding therapeutic options for patients with pancreatic adenocarcinoma—a cancer traditionally considered difficult to treat.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT